Federico Cappuzzo, MD, PhD, AUSL della Romagna-Ravenna, Ravenna, Italy, discusses the current treatment recommendations for EGFR mutations in non-small cell lung cancer (NSCLC) and future direction. EGFR-mutant NSCLC in the first-line setting is currently osimertinib, which demonstrates a tolerable safety profile and efficacy in both the early-stage and metastatic setting. Unfortunately, patients undergoing treatment with osimertanib almost inevitably relapse due to the development of acquired resistance. Thus, Dr Cappuzzo highlights the importance of uncovering new agents that are effective at the time of osimertinib failure, as well as agents that are more potent than osimertanib. This interview took place at the IASLC 2022 World Conference on Lung Cancer congress in Vienna, Austria.